Printer Friendly

DEFINITIVE ACQUISITION AGREEMENT SIGNED BETWEEN ROBERTS PHARMACEUTICALS AND NATIONAL CLINICAL RESEARCH CENTERS

DEFINITIVE ACQUISITION AGREEMENT SIGNED BETWEEN ROBERTS PHARMACEUTICALS
 AND NATIONAL CLINICAL RESEARCH CENTERS
 EATONTOWN, N.J., March 23 /PRNewswire/ -- As a follow-up to the previously announced Letter of Intent (Jan. 14, 1992), Roberts Pharmaceutical Corporation (NASDAQ: RPCX) of Eatontown announced today that Roberts and National Clinical Research Centers, Inc. ("NCRC"), of Bethesda, Md., have signed a definitive agreement for the acquisition of NCRC by Roberts Pharmaceuticals for a purchase price of $6,250,000, consisting of $2 million in cash and $4,250,000 in Roberts common stock.
 NCRC, founded in 1985, is a privately owned clinical trials management organization which provides services to the pharmaceutical industry with concentrated emphasis on methodologies for the rapid completion of Phase II - IV clinical trials. In the Trial Management Organization ("TMO") concept, NCRC has what it believes is a unique system for assisting pharmaceutical companies in obtaining more rapid approval for new drugs. Its methodology of conducting clinical research through ten research-dedicated outpatient clinics; an in-house patient recruiting system; computerized study tracking system; on-site study coordinators with qualified contract investigators; multi-level quality control; and sophisticated data management provides pharmaceutical firms with advantages of speed and quality control. The acquisition, which is expected to be completed within the next several weeks, is subject to approval by NCRC shareholders and other conditions of closing. NCRC had 1991 sales of just over $6 million and has a staff of approximately 70 employees.
 In commenting on the reasons for this acquisition, Robert A. Vukovich, Roberts chairman and CEO, stated, "This area of Roberts' growth was targeted because it addresses the most time-consuming segment of the development process. The TMO concept is ready for expansion and, as a result, will greatly assist Roberts' drug development capabilities for its own new drug pipeline."
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non-prescription pharmaceuticals in the United States and abroad.
 -0- 3/23/92
 /CONTACT: Anthony P. Maris of Roberts, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corp.; National Clinical Research Centers,
 Inc. ST: New Jersey, Maryland IN: MTC SU: TNM


GK-OS -- NY048 -- 0591 03/23/92 13:02 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 23, 1992
Words:390
Previous Article:GENERAL INSTRUMENT AND MIT MAKE BROADCASTING HISTORY WITH FIRST DIGITAL HIGH-DEFINITION TELECAST
Next Article:BARCOLENE/PENN CHAMP AND FOUNTAIN PHARMACEUTICALS TEAM UP FOR EXCITING NEW SUNTAN PROGRAM
Topics:


Related Articles
ROBERTS PHARMACEUTICAL CORPORATION TO ACQUIRE NATIONAL CLINICAL RESEARCH CENTERS
YAMANOUCHI PHARMACEUTICAL CO. AND ROBERTS PHARMACEUTICALS SIGN DEFINITIVE EQUITY INVESTMENT AGREEMENT
ROBERTS PHARMACEUTICAL COMPLETES ACQUISITION OF NATIONAL CLINICAL RESEARCH CENTERS, INC.
Xenon Genetics and RGS Genome Combine To Create World-Leading Clinical Genomics Company.
BioMarin Completes Acquisition of Enzyme Products From IBEX Technologies.
Bioinformatics company to buy CRO. (Executive briefing: news, trends & market intelligence for instrument executives).
Mutual Pharmaceutical Company Launches Doxycycline Hyclate 20mg Tablets Under License and Supply Agreement.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters